No Independent Association of Alanine Aminotransferase With Risk of Future Type 2 Diabetes in the Hoorn Study
- Roger K. Schindhelm, BSC, MD1,
- Jacqueline M. Dekker, PHD2,
- Giel Nijpels, MD, PHD23,
- Robert J. Heine, MD, PHD12 and
- Michaela Diamant, MD, PHD1
- 1Department of Endocrinology, VU University Medical Center, Amsterdam, the Netherlands
- 2Institute for Research in Extramural Medicine, VU University Medical Center, Amsterdam, the Netherlands
- 3Department of General Practice, VU University Medical Center, Amsterdam, the Netherlands
- Address correspondence to Roger K. Schindhelm, VU University edical Center, Department of Endocrinology, P.O. Box 7007, 1007 MB msterdam, Netherlands. E-mail: rk.schindhelm{at}vumc.nl
We read with great interest the article by Nannipieri et al. (1), which reported no association between aspartate aminotransferase, alanine aminotransferase (ALT), or alkaline phosphatase and the 7-year incidence of impaired glucose tolerance and type 2 diabetes. Interestingly, γ-glutamyltransferase was, but ALT was not, a significant predictor of impaired glucose tolerance or type 2 diabetes. This is, as the authors stated, in contrast to previously published papers that found significant prospective associations of ALT with incident type 2 diabetes after adjustment for obesity, insulin sensitivity, or inflammation (C-reactive protein) (2–4). We studied the …
